PACTR202003507062297OtherPhase 4
Evaluation of open-label Pre exposure prophylaxis (PrEP) delivery amongKenyan women
niversity of Washington0 sites1,000 target enrollmentStarted: March 12, 2020Last updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Other
- Sponsor
- Enrollment
- 1,000
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 19 Year(s) to 44 Year(s) (—)
- Sex
- Female
Inclusion Criteria
- •For HIV uninfected women
- •-Age 16-25
- •o16 and 17 year olds, where permissible by national regulations and local IRB approval
- •-Able and willing to provide written informed consent
- •-Recently sexually active (defined as having had vaginal intercourse at least once in the previous three months)
- •-HIV uninfected based on negative HIV rapid tests, on the date of enrollment
Exclusion Criteria
- •Not within the required age range
- •Not willing to provide informed consent
- •Not sexually active
- •HIV infected
Investigators
Similar Trials
Active, not recruiting
Not Applicable
An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the Efficacy, Safety and Pharmacokinetics of B-Domain Deleted Recombinant Factor VIII Albumin Free (Moroctocog alfa [AF-CC]) in Children With Hemophilia A - N/AYounger Male Haemophilia A patients < 6 years of age with moderately severe to severe hemophilia A (FVIII:C = 2%), with previous FVIII replacement therapy experience (= 50 exposure days to any FVIII replacement product).EUCTR2006-005575-17-DEWyeth Pharmaceuticals Inc. acting through its division Wyeth Research, a Pfizer Company72
Active, not recruiting
Phase 1
An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the , Efficacy, Safety and Pharmacokinetics of B Domain Deleted Recombinant Factor VIII Albumin Free (ReFacto AF) in Children With Hemophilia A Estudio abierto para evaluar el tratamiento profiláctico y para caracterizar la eficacia, la seguridad y la farmacocinética del factor VIII recombinante con delección del dominio B sin albúmina (ReFacto® AF) en niños con hemofilia A - N/AEUCTR2006-005575-17-ESWyeth Research Division of Wyeth Pharmaceuticals Inc.65
Active, not recruiting
Not Applicable
An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the Efficacy, Safety, and Pharmacokinetics of B Domain Deleted Recombinant Factor VIII Albumin Free (Moroctocog alfa [AF-CC]) in Children With Hemophilia A - NDHemophilia AMedDRA version: 12.0Level: LLTClassification code 10056493Term: Haemophilia A without inhibitorsEUCTR2006-005575-17-ITWyeth Research Division of Wyeth Pharmaceuticals Inc.72
Active, not recruiting
Phase 1
A study to compare the difference in effect between treating bleeds after they occur or giving preventative treatment on an ongoing basis, also to determine levels of Factor VIII in the blood following treatment in children with Hemophilia AEUCTR2006-005575-17-ATWyeth Pharmaceuticals Inc. acting through its division Wyeth Research, a Pfizer Company72
Completed
Not Applicable
An open-label, non-controlled trial of prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation.Invasive fungal infectionJPRN-UMIN000027218ational Hospital Organization Nagoya Medical Center30